Skip to content
lifestyle.buyersdesire.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Erasca, Inc.
Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium
September 10, 2026
Erasca to Present at Morgan Stanley Healthcare Conference on RAS/MAPK Oncology
September 8, 2026
Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma
August 24, 2026
Erasca Reports Second Quarter 2026 Business Updates and Financial Results
August 11, 2026
Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 10, 2026
Erasca Strengthens R&D Leadership with Appointment of Internationally Recognized Medical Oncologist Charles S. Fuchs, M.D., M.P.H., as President of R&D
August 10, 2026
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
July 15, 2026
Erasca Announces Pricing of Upsized Public Offering of Common Stock
July 13, 2026
Erasca Announces Proposed Public Offering of $500 Million of Common Stock
July 13, 2026
Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
July 13, 2026
1
2
Next Page
→